DEM Biopharma, Inc. Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
DEM Biopharma, Inc. is a biotechnology research company based in Cambridge, Massachusetts, focused on developing next-generation cancer therapeutics. Its lead program, DEM301, is an antibody-drug conjugate designed to target a novel extracellular protein overexpressed in gastrointestinal and other malignancies, potentially addressing unmet needs in oncology patients. The company positions itself within the biopharma landscape by pursuing targeted therapies that aim to improve treatment options for cancer, with a particular emphasis on gastrointestinal cancers. DEM Biopharma operates with a relatively small team and maintains a presence in the Cambridge area, reflecting its early-stage scientific focus. A recent development includes a poster presentation about DEM301 at the 2026 ASCO Gastrointestinal Cancers Symposium, indicating ongoing dissemination of its research within the oncology community.